Skip To Main Content

Explore VEGF

Angiogenesis is a hallmark of tumor development

Critical questions in the science of VEGF and angiogenesis

1. What is the significance of VEGF (vascular endothelial growth factor) in tumor angiogenesis?

VEGF angiogenesis

As demonstrated in preclinical models:

VEGF has been identified as a regulator of tumor angiogenesis.1

 

2. Why is VEGF essential throughout the tumor life cycle?

VEGF tumor lifecycle

As demonstrated in preclinical models:

VEGF may play an essential role throughout the tumor cycle by helping tumor vessels establish, grow, and survive.2,3

 

3. What are the effects of VEGF inhibition?

VEGF inhibition

Angiogenesis: a necessary part of the process in the progression of cancer4

Figure 1. Tumor angiogenesis

Tumor angiogenesis

Angiogenesis is a hallmark of tumor development

Angiogenesis is a necessary part of the process in the progression of cancer from small, localized neoplasms to larger, growing, and potentially metastatic tumors. To grow beyond 1 to 2 mm in diameter, a tumor needs an independent blood supply, which is acquired by the expression of growth factors that recruit new vasculature from existing blood vessels (Figure 1). This process continues even as the tumor matures. Thus, upregulation of angiogenesis is a key step in sustained tumor growth and may also be critical for tumor metastasis.1,4

VEGF is an activator of tumor angiogenesis4

VEGF (also known as VEGF-A, but commonly referred to simply as VEGF) stands for "vascular endothelial growth factor." As its name suggests, VEGF stimulates vascular endothelial cell growth, survival, and proliferation.3,5

VEGF is a member of a family of 6 structurally related proteins (Table 1) that regulate the growth and differentiation of multiple components of the vascular system, especially blood and lymph vessels. The angiogenic effects of the VEGF family are thought to be primarily mediated through the interaction of VEGF with VEGFR-2.5-8

Table 1. The VEGF protein family5-7,9,10

VEGF ligands

Receptors

Functions

VEGF (VEGF-A)

VEGFR-1, VEGFR-2, neuropilin-1

Angiogenesis
Vascular maintenance

VEGF-B

VEGFR-1

Not established

VEGF-C

VEGFR-3

Lymphangiogenesis

VEGF-D

VEGFR-3

Lymphangiogenesis

VEGF-E (viral factor)

VEGFR-2

Angiogenesis

Placental growth factor

VEGFR-1, neuropilin-1

Angiogenesis
Inflammation

The VEGF signaling pathway

VEGF ligands mediate their angiogenic effects by binding to specific VEGF receptors, leading to subsequent signal transduction.11

VEGF signaling pathway
  1. Upstream activators stimulate the production of VEGF.
  2. VEGF binds to receptors on endothelial cells.
  3. Angiogenesis is mediated primarily through the interaction of VEGF-A with VEGFR-2.
  4. Other variants of the VEGF ligand and receptor play a secondary role in this process.

As demonstrated in preclinical models, VEGF plays a central role in tumor development

VEGF may affect tumor vasculature in 3 essential ways7:

  1. Early in tumor development, VEGF may help establish new vasculature.
  2. As the vasculature network develops, VEGF may continue to help new vasculature grow, providing the blood supply needed to drive further tumor growth and metastasis.
  3. Throughout tumor development, VEGF may also help existing vasculature survive, allowing tumors to sustain their metabolic requirements over their entire life cycle.

As the tumor develops, it may begin to activate secondary angiogenic pathways, such as basic fibroblast growth factor (bFGF), transforming growth factor beta (TGFβ), placental growth factor (PlGF), and platelet-derived endothelial cell growth factor (PD-ECGF). As these secondary pathways emerge, VEGF continues to be expressed and remains one of the critical mediators of angiogenesis (Figure 1).12

Figure 1. Continuous VEGF expression throughout tumor development12-13

Continuous VEGF expression throughout tumor development

The role of VEGF across tumor types, as demonstrated in preclinical models

Expression of VEGF has been observed across a range of tumor types and has been widely correlated with tumor development and/or poor cancer prognosis.4,5,7

Inhibition of new and recurrent tumor vessel growth, as demonstrated in preclinical models

Targeting VEGF may result in ongoing inhibition of both new and recurrent tumor vessel growth (Table 1). It has been proposed that these effects may help inhibit tumor growth and metastasis.1,14

Research also suggests that blockade of VEGF signaling may help inhibit tumor growth by preventing new vessel growth at both primary and metastatic sites.1

Table 1. Proposed effects of VEGF inhibition15,16

Tumor vessel inhibition

Tumor vessel regression

Interferes with the ability of VEGF to help tumor vessels establish and grow

Associated with reduced tumor growth and decreased metastatic potential

Interferes with the ability of VEGF to help tumor vessels survive

Associated with reduction in microvascular density and tumor volume

Regression of existing tumor vasculature, as demonstrated in preclinical models14

Based on preclinical models, it has also been proposed that VEGF inhibition may regress existing tumor vessels (Table 1). These reductions in microvascular density have been associated with a reduction in tumor volume and weight (Figure 1).14,17

Figure 1. Microcomputed tomography image showing effect of VEGF inhibition in a preclinical model3

Control tumor (no VEGF inhibition)
    • Borgström P, Hillan KJ, Sriramarao P, Ferrara N. Cancer Res. 1996;56:4032-4039. PMID: 8752175

      Borgström P, Hillan KJ, Sriramarao P, Ferrara N. Cancer Res. 1996;56:4032-4039. PMID: 8752175

    • Ellis LM, Hicklin DJ. Nat Rev Cancer. 2008;8:579-591. PMID: 18596824

      Ellis LM, Hicklin DJ. Nat Rev Cancer. 2008;8:579-591. PMID: 18596824

    • O’Connor JPB, Carano RAD, Clamp AR, et al. Clin Cancer Res. 2009;15:6674-6682. PMID: 19861458

      O’Connor JPB, Carano RAD, Clamp AR, et al. Clin Cancer Res. 2009;15:6674-6682. PMID: 19861458

    • Nishida N, Yano H, Nishida T, et al. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213-219.
      PMID: 17326328

      Nishida N, Yano H, Nishida T, et al. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213-219.
      PMID: 17326328

    • Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23:1011-1027. PMID: 15585754

      Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23:1011-1027. PMID: 15585754

    • Nurmi H, Saharinen P, Zarkada G, Zheng W, Robciuc MR, Alitalo K. VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption. EMBO Mol Med. 2015;7(11):1418-1425. PMID: 26459520

      Nurmi H, Saharinen P, Zarkada G, Zheng W, Robciuc MR, Alitalo K. VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption. EMBO Mol Med. 2015;7(11):1418-1425. PMID: 26459520

    • Ferrara N. Endocr Rev. 2004;25:581-611. PMID: 15294883

      Ferrara N. Endocr Rev. 2004;25:581-611. PMID: 15294883

    • Stimpfl M, Tong D, Fasching B, et al. Clin Cancer Res. 2002;8:2253-2259. PMID: 12114428

      Stimpfl M, Tong D, Fasching B, et al. Clin Cancer Res. 2002;8:2253-2259. PMID: 12114428

    • Christinger HW1, Fuh G, de Vos AM, et al. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem. 2004;279(11):10382-10388. PMID: 14684734

      Christinger HW1, Fuh G, de Vos AM, et al. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem. 2004;279(11):10382-10388. PMID: 14684734

    • Bautch VL. VEGF-directed blood vessel patterning: from cells to organism. Cold Spring Harb Perspect Med. 2012;2(9):a006452. doi:10.1101/cshperspect.a006452. PMID: 22951440

      Bautch VL. VEGF-directed blood vessel patterning: from cells to organism. Cold Spring Harb Perspect Med. 2012;2(9):a006452. doi:10.1101/cshperspect.a006452. PMID: 22951440

    • Abhinand CS, Raju R, Soumya SJ, et al. VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal. 2016;10(4):347-354. PMID: 27619687

      Abhinand CS, Raju R, Soumya SJ, et al. VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal. 2016;10(4):347-354. PMID: 27619687

    • Folkman J. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Vol 2. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:2865-2882.

      Folkman J. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Vol 2. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:2865-2882.

    • Fontanini G, Vignati S, Boldrini L, et al. Clin Cancer Res. 1997;3:861-865. PMID: 9815760

      Fontanini G, Vignati S, Boldrini L, et al. Clin Cancer Res. 1997;3:861-865. PMID: 9815760

    • Warren RS, Yuan H, Matli MR, et al. J Clin Invest. 1995;95:1789-1797. PMID: 7535799

      Warren RS, Yuan H, Matli MR, et al. J Clin Invest. 1995;95:1789-1797. PMID: 7535799

    • Yuan F, Chen Y, Dellian M, et al. Proc Natl Acad Sci U S A. 1996;93:14765-14770. PMID: 8962129

      Yuan F, Chen Y, Dellian M, et al. Proc Natl Acad Sci U S A. 1996;93:14765-14770. PMID: 8962129

    • Borgström P, Bourdon MA, Hillan KJ, et al. Prostate. 1998;35:1-10. PMID: 9537593

      Borgström P, Bourdon MA, Hillan KJ, et al. Prostate. 1998;35:1-10. PMID: 9537593

    • Tobelem G. Targ Oncol. 2007;2:153-164.

      Tobelem G. Targ Oncol. 2007;2:153-164.

    Antibodies icon

    Emerging development platforms

    Discover our broad range of antitumor modalities.

    Microscope icon

    Discover cancer biomarkers

    Learn more about the importance of cancer biomarkers.